Introduction: This chapter describes the characteristics of adult patients starting renal replacement therapy (RRT) in the UK in 2011 and the incidence rates for RRT in Primary Care Trusts and Health Boards (PCT/HBs) in the UK.
Methods: Basic demographic and clinical characteristics are reported on patients starting RRT at all UK renal centres. Presentation time, defined as time between first being seen by a nephrologist and start of RRT, was also studied. Age and gender standardised ratios for incidence rates in PCT/HBs were also calculated.
Results: In 2011, the incidence rate in the UK was similar to 2010 at 108 per million population (pmp). There were wide variations between PCT/HBs in standardised incidence ratios. For the 2006-2011 incident cohort analysis the range was 0.42 to 2.52 (IQR 0.85, 1.20). The median age of all incident patients was 64.9 years (IQR 50.9, 75.1). For transplant centres this was 63.8 years (IQR 49.5, 74.3) and for non-transplanting centres 66.2 years (IQR 52.4, 76.0). The median age for non-Whites was 58.4 years. Diabetic renal disease remained the single most common cause of renal failure (25%). By 90 days, 67.1% of patients were on haemodialysis, 19.2% on perito- neal dialysis, 7.8% had had a transplant and 5.8% had died or stopped treatment. This is the second year in a row that the percentage on peritoneal dialysis has increased and, in 2011, this was most notable in the 65-74 age group. There was a lot of variability in use of PD with some centres having over twice the average percentage on PD. The mean eGFR at the start of RRT was 8.7 ml/min/1.73 m(2) similar to the previous four years. Late presentation (<90 days) fell from 23.9% in 2006 to 19.6% in 2011. There was no relationship between social deprivation and presentation pattern.
Conclusions: Incidence rates have plateaued in England over the last six years. There has been an increase in the percentage of new patients still on RRT at 90 days after starting who were on PD at 90 days (19.2 to 20.4%).
Copyright © 2013 S. Karger AG, Basel.